HC Wainwright Has Bearish Estimate for Precigen Q1 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Equities researchers at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for Precigen in a report issued on Thursday, March 20th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of ($0.08) per share for the quarter, down from their prior forecast of ($0.04). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at ($0.06) EPS.

Precigen (NASDAQ:PGEN) last announced its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.02. The company had revenue of $1.19 million for the quarter, compared to analysts’ expectations of $1.30 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%.

Separately, JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of Precigen in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Precigen Trading Up 0.6 %

PGEN opened at $1.82 on Monday. Precigen has a twelve month low of $0.65 and a twelve month high of $2.17. The firm has a market capitalization of $535.16 million, a PE ratio of -3.31 and a beta of 1.58. The firm’s 50-day moving average price is $1.62 and its 200 day moving average price is $1.16.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Envestnet Asset Management Inc. raised its stake in Precigen by 29.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 5,915 shares during the period. Invesco Ltd. raised its position in shares of Precigen by 14.6% during the 4th quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 6,040 shares during the period. ProShare Advisors LLC raised its position in shares of Precigen by 26.6% during the 4th quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 10,900 shares during the period. Stoneridge Investment Partners LLC lifted its holdings in Precigen by 21.3% in the fourth quarter. Stoneridge Investment Partners LLC now owns 68,681 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 12,063 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in Precigen by 12.0% in the fourth quarter. Wells Fargo & Company MN now owns 114,558 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 12,285 shares during the period. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.